Amphetamine oral- Alcobra

Drug Profile

Amphetamine oral- Alcobra

Alternative Names: Abuse-Deterrent, Amphetamine Immediate-Release - Alcobra; ADAIR

Latest Information Update: 11 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alcobra
  • Developer Alcobra; Capsugel
  • Class Amphetamines; Small molecules
  • Mechanism of Action Adrenergic receptor agonists; Central nervous system stimulants; Trace amine-associated receptor 1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Attention-deficit hyperactivity disorder

Most Recent Events

  • 06 Jul 2017 Capsugel has been acquired by Lonza
  • 30 May 2017 Alcobra announces intention to submit IND to US FDA for Attention-deficit hyperactivity disorder in third quarter of 2017
  • 28 Apr 2017 Alcobra plans a bioequivalence trial for attention deficit hyperactivity disorder in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top